Shivu Kaushik, MD
Pulmonary Disease · Fort Wayne, INNPI 1871709295
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $8,134 and has fallen 92.9% since, to $576 in 2025.
Across 98 payments — averaging $105.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$450
- Bayer$400
- Boehringer Ingelheim$282
- Mallinckrodt Hospital Products Inc.$263
- Takeda Pharmaceuticals U.S.A., Inc.$207
- plus $1K from 17 others
What the payments were for
- Consulting fees$4004%
- Travel & lodging$1,46414%
- Food & beverage$2,27322%
- Education$6,18660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $7,507 |
| AstraZeneca | 21 | $450 |
| Bayer | 2 | $400 |
| Boehringer Ingelheim | 5 | $282 |
| Mallinckrodt Hospital Products Inc. | 4 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $207 |
| Johnson & Johnson | 3 | $178 |
| United Therapeutics Corporation | 4 | $168 |
| GSK | 9 | $153 |
| Sanofi | 5 | $95 |
| Genentech USA, Inc. | 2 | $86 |
| Insmed, Inc. | 4 | $75 |
| Grifols USA, LLC | 3 | $70 |
| Pulmonx Corporation | 3 | $54 |
| Abiomed | 2 | $53 |
| Philips North America LLC | 3 | $51 |
| Merck | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Amgen | 2 | $38 |
| Galvanize Therapeutics, Inc | 1 | $37 |
| Viatris Specialty LLC | 2 | $30 |
| Electromed, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,296
- ION$3,000
- Adempas$400
- Monarch Platform$130
- GLASSIA$122
- ACTHAR$121
- TEZSPIRE$102
How this compares
$10,323 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 12 | $164,682 |
| OfevNintedanib Esylate | 11 | $140,103 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $82,429 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 107 | $67,869 |
| Spiriva RespimatTiotropium Bromide | 66 | $48,770 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $41,305 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $37,830 |
| Arnuity ElliptaFluticasone Furoate | 67 | $18,124 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,274 |
| Pirfenidone | 18 | $13,513 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $6,793 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,202 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $3,353 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,238 |
| Roflumilast | 23 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $282 | $256,742184 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $153 | $183,890316 claims |
| BayerAdempas | $400 | $164,68212 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $450 | $23,06742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Fort Wayne
- Daria LeeFort Wayne$69K
- Abhishek BiswasFort Wayne$30K
- Vatche IsrabianFort Wayne$22K
- Vicente RodriguezFort Wayne$10K
- Manuel MartinezFort Wayne$9K
- Eric PetersonFort Wayne$9K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.